<DOC>
	<DOCNO>NCT01627041</DOCNO>
	<brief_summary>This randomized phase II trial study well decitabine work give together daunorubicin hydrochloride cytarabine treat patient acute myeloid leukemia . Drugs use chemotherapy , decitabine , daunorubicin hydrochloride , cytarabine , work different way stop growth cancer cell , either kill cell stop dividing . Decitabine may help daunorubicin hydrochloride cytarabine kill cancer cell make sensitive drug . It yet know whether low-dose decitabine effective high-dose decitabine give together daunorubicin hydrochloride cytarabine treat acute myeloid leukemia .</brief_summary>
	<brief_title>Decitabine , Cytarabine , Daunorubicin Hydrochloride Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary I . To `` Pick Winner '' decide whether development epigenetic priming decitabine prior standard `` 7+3 '' induction chemotherapy pursue . Secondary I . To determine whether epigenetic priming decitabine prior standard cytarabine daunorubicin hydrochloride `` 7+3 '' induction chemotherapy sufficient efficacy warrant development assess overall CR1 rate ≥ 50 % . II . To establish safety expect toxicity decitabine use prim cytarabine daunorubicin hydrochloride `` 7+3 '' induction chemotherapy acute myeloid leukemia ( AML ) . III . To assess pharmacodynamics deoxyribonucleic acid ( DNA ) hypomethylation decitabine administer short infusion . IV . To investigate , select case , molecular cellular consequence decitabine-induced hypomethylation assess effect decitabine-mediated hypomethylation transcriptional pattern AML cell , determine effect hypomethylation differentiation and/or apoptosis leukemic blast . ( exploratory ) V. To identify biomolecular correlate treatment response ( biomarkers ) induction chemotherapy AML base upon epigenetic pattern DNA methylation AML specimen obtain prior treatment . ( exploratory ) OUTLINE : This multicenter study . Patients stratify accord age ( less 50 year vs 50-65 year ) , white blood cell count ( ≤ 30 K/mL v great 30 K/mL ) , cytogenetic risk group ( intermediate v adverse risk ) , antecedent hematological condition precede diagnosis acute myeloid leukemia ( yes v ) . Patients randomize 1 2 treatment arm . Arm I : Patients receive induction chemotherapy comprise daunorubicin hydrochloride intravenously ( IV ) daily day 1-3 cytarabine IV continuously day 1-7 absence disease progression unacceptable toxicity . Patients achieve complete remission ( CR ) first induction-chemotherapy course receive second identical induction course . Arm II : Patients receive decitabine IV 1 hour day -5 -1 . Patients receive induction chemotherapy arm I absence disease progression unacceptable toxicity . Patients achieve CR first induction-chemotherapy course receive second identical induction course . Patients undergo blood , bone marrow , oral mucosa cell sample collection baseline , prior induction therapy , treatment DNA methylation study pharmacodynamic study . After completion study treatment , patient follow 10 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia ( AML ) define World Health Organization Molecular AMLrisk group lessthanfavorable define follow criterion : The absence goodrisk karyotype ( 8 ; 21 ) , inv ( 16 ) , ( 16 ; 16 ) , ( 15 ; 17 ) identify metaphase karyotype The absence ( 8 ; 21 ) , inv ( 16 ) , ( 16 ; 16 ) , ( 15 ; 17 ) identify fluorescent situ hybridization ( FISH ) The absence correspond fusion transcript , AML1eighttwentyone corepressor ( ETO ) , corebinding factor , beta subunit ( CBFβ ) smooth muscle myosin heavy chain ( SMMHC ) , progressive multifocal leukoencephalopathy ( PML ) retinoic acid receptor alpha ( RARa ) , identified reverse transcriptasepolymerase chain reaction ( RTPCR ) Patient acute promyelocytic leukemia ( APL , FrenchAmericanBritish [ FAB ] M3 ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ( Karnofsky ≥ 60 % ) Adequate cardiac function define either follow : An echocardiogram demonstrate ejection fraction within normal limit A multi gate acquisition ( MUGA ) scan demonstrate ejection fraction within normal limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) ≤ 2.5 time institutional upper limit normal ( ULN ) Creatinine ≤ 2 mg/dL OR creatinine clearance ≥ 50 mL/min Total bilirubin ≤ 2 time ULN Patients document diagnosis Gilbert syndrome result elevated total bilirubin level eligible , provide eligibility criterion meet Patients total bilirubin 23 mg/dL direct ( conjugate ) bilirubin normal range eligible , provide eligibility criterion meet Pregnant nursing subject may enrol pregnancy must avoid ; woman childbearing potential—defined sexually active woman undergone hysterectomy menses time within precede 24 months—must negative serum urine pregnancy test within 7 day prior registration ; woman men childbearing potential must either commit continued abstinence heterosexual intercourse commit two acceptable method birth control—one highly effective method ( e.g. , IUD , oral nonoral hormonal contraceptive , tubal ligation partner 's vasectomy ) one additional effective method ( e.g. , latex condom , diaphragm cervical cap ) time time screen final Treatment Response Assessment NOTE : woman become pregnant suspect pregnant partner participate study , subject inform treat physician immediately NOTE : effect decitabine develop human fetus unknown know teratogen mammal ( mouse ) Ability understand willingness sign write informed consent document Chemotherapy ( hydroxyurea ) radiation within 2 week prior plan therapy study ongoing adverse event due agent administer 2 week earlier Concurrent treatment investigational agent permit Cumulative lifetime dose anthracycline chemotherapeutic &gt; 80 mg/m^2 History allergic reaction attribute compound similar chemical biologic composition decitabine , cytarabine daunorubicin Uncontrolled intercurrent illness consider investigator constitute unwarranted high risk investigational drug treatment ; example include , limited following : Uncontrolled serious infection ; Unstable angina pectoris ; Uncontrolled cardiac arrhythmia ; Active second malignancy require treatment ; Symptomatic congestive heart failure HIVpositive subject CD4 count &lt; 200 cells/μL exclude due increase risk lethal infection treat marrowsuppressive chemotherapy ( 87 ) NOTE : subject HIV infection CD4 count &gt; = 200 cells/μL eligible combination antiretroviral therapy hold administration chemotherapy due potential pharmacokinetic interaction decitabine , cytarabine daunorubicin . Antiretroviral therapy may resume 24 hour completion last dose induction chemotherapy Subject psychiatric disorder , alter mental status social situation would preclude understand informed consent process and/or limit compliance study requirement Subject inability unwillingness , opinion investigator , comply protocol requirement Subjects central nervous system ( CNS ) ( leptomeningeal ) infiltration AML may consider treatment Investigator 's discretion follow discussion Principle Investigator ; neurologic deficit must note prior enrollment study Subject circulate blast count &gt; 50,000/μL ( subject may enrol circulate blast count control hydroxyurea and/or , clinically indicate , leukophoresis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>